Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001780081-26-000006 · form4-06052026_080620.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:56 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 33,243 | $39.74 | $1,320,963.79 |
DisclosureSEC source: 0001780081-26-000004 · form4-03122026_080302.xml · nonDerivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,302 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.11 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 7,229 | $39.66 | $286,715.15 |
DisclosureSEC source: 0001780081-26-000002 · form4-03042026_090337.xml · nonDerivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,545 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.80 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:06 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 40,472 | $29.72 | $1,202,718.57 |
DisclosureSEC source: 0001780081-25-000006 · form4-11262025_091144.xml · nonDerivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,774 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.12 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:22 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 20,682 | $27.34 | $565,365.22 |
DisclosureSEC source: 0001780081-25-000004 · form4-11182025_091122.xml · nonDerivative · entry 2 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 364,246 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.88 per share, inclusive. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:22 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 19,790 | $26.61 | $526,693.04 |
DisclosureSEC source: 0001780081-25-000004 · form4-11182025_091122.xml · nonDerivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,928 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.975 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 00:34 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,747 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001415889-25-015699 · form4-06052025_120617.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,747 Underlying: Common Stock · 29,747 shares Expires 2035-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,639 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001415889-24-015962 · form4-06072024_080601.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,639 Underlying: Common Stock · 7,639 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037532 · doc4.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001209191-22-035076 · doc4.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 08, 2021 Filed Jun 25, 2021 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-21-043332 · doc4.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001209191-20-034731 · doc4.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,777 Underlying: Common Stock · 14,777 shares Expires 2030-06-02 F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 00:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0001567619-19-018220 · doc1.xml · derivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,777 Underlying: Common Stock · 14,777 shares Expires 2029-09-09 F1 · derivative.exercise_date: This option vests 100% and becomes exercisable on June 21, 2020, subject to reporting person's continued service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.